5061972026-04-012026-06-305061972026-04-012026-06-30in-capmkt:OtherExpenses1Member5061972026-04-012026-06-30in-capmkt:OtherExpenses2Member5061972026-04-012026-06-30in-capmkt:OtherExpenses3Member5061972026-04-012026-06-30in-capmkt:OtherExpenses4Member5061972026-04-012026-06-30in-capmkt:OtherExpenses5Member5061972026-04-012026-06-30in-capmkt:OtherExpenses6Member5061972026-04-012026-06-30in-capmkt:OtherExpenses7Member5061972026-04-012026-06-30in-capmkt:OtherExpenses8Member5061972026-04-012026-06-30in-capmkt:OtherExpenses9Member5061972026-04-012026-06-30in-capmkt:OtherExpenses10Member5061972026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15061972026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares506197BLISSGVSNOTLISTEDINE416D01022BLISS GVS PHARMA LIMITEDMain BoardEquity2026-04-012027-03-312026-08-122026-08-05INRLakhsQuarterlyFirst quarterSingle segmentPharmaceutical & Healthcare2026-08-1216:22:002026-08-1218:15:00Not applicable2026-04-012026-06-30UnauditedConsolidated285575600095997000295175300094636500015098100047099000430472000579400099375000516836000219692200075483100007548310001663290007478200024111100005137200000000513720000-21794000491926000500974000127460004791800001274600010605600014.734.65004.734.65Notes: <br /> 1. The above un-audited standalone and consolidated financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 12, 2026. These standalone and consolidated un-audited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India. <br /> 2. The above un-audited standalone and consolidated financial results for the quarter ended June 30, 2026 are prepared in compliance with the Ind AS which have been subjected to a limited review by the statutory auditors of the Company. The statutory auditors have issued limited review reports with unmodified conclusion on the un-audited standalone and consolidated financial results. <br /> 3. As the Group's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment information is disclosed. <br /> 4. Employee Benefit Expenses includes Share Based Payment expense on account of ESOP Scheme, 2019 of Rs 297.04 Lakh (quarter ended June 30, 2025 Rs. 140.07 Lakh) as per Ind AS 102 "Share based Payment" for the quarter ended June 30, 2026. <br /> 5.Pursuant to the implementation of the New Labour Codes with effect from November 21, 2025, the Company and the Group had reassessed its employee benefit obligations and recognised an incremental expense of Rs. 215.55 Lakh and Rs. 248.71 Lakh in standalone and consolidated financials respectively for the year ended March 31, 2026, under Exceptional Items as past service cost. <br /> 6. During the quarter ended June 30, 2026, the Company has allotted 2,67,250 equity shares of Rs. 1 each fully paid, on exercise of stock options by employees in accordance with the Company's ESOP Scheme, 2019. The outstanding number of options as at June 30, 2026 are 22,36,250. <br /> 7. The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full financial year and the published year to date un-audited figures upto the third quarter of the previous financial year, which were subject to limited review.Freight outward101114000ECL expenses59650000Travelling and Conveyance expenses26553000Repairs and Maintenance36147000Power and Fuel63106000Business Development expenses113403000Corporate Social Responsibility expenses145000Sales Promotion expenses7015000Legal and Professional Charges51120000Others58583000Remeasurement of the defined benefit liabilities/ (asset)-8634000-8634000-2173000Exchange differences in translating the Financial Statements of Foreign Operations-15333000-153330000-21794000